Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) and VistaGen Therapeutics (NASDAQ:VTGN – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.
Earnings and Valuation
This table compares Madrigal Pharmaceuticals and VistaGen Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Madrigal Pharmaceuticals | $958.40 million | 10.37 | -$288.28 million | ($12.89) | -33.39 |
| VistaGen Therapeutics | $1.27 million | 5.88 | -$69.68 million | ($1.66) | -0.10 |
VistaGen Therapeutics has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Madrigal Pharmaceuticals has a beta of -1.04, meaning that its stock price is 204% less volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings for Madrigal Pharmaceuticals and VistaGen Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Madrigal Pharmaceuticals | 1 | 2 | 15 | 0 | 2.78 |
| VistaGen Therapeutics | 1 | 4 | 0 | 0 | 1.80 |
Madrigal Pharmaceuticals currently has a consensus price target of $699.20, indicating a potential upside of 62.47%. VistaGen Therapeutics has a consensus price target of $0.95, indicating a potential upside of 464.47%. Given VistaGen Therapeutics’ higher probable upside, analysts plainly believe VistaGen Therapeutics is more favorable than Madrigal Pharmaceuticals.
Institutional & Insider Ownership
98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Madrigal Pharmaceuticals and VistaGen Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Madrigal Pharmaceuticals | -25.32% | -56.65% | -25.53% |
| VistaGen Therapeutics | -2,702.64% | -152.59% | -117.45% |
Summary
Madrigal Pharmaceuticals beats VistaGen Therapeutics on 9 of the 14 factors compared between the two stocks.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
About VistaGen Therapeutics
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
